{"transactions":[{"id":931954,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":68857,"kind":"person","name":"Harsh Michael","position":1,"cik":"0001706155","reported_name":"Harsh Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-24T00:43:37.000Z","date":"2026-01-21","kind":"grant","planned":false,"acquired":true,"shares":60324,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Holdings include unvested restricted stock units (\"RSUs\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents RSUs that convert to common stock on a one-for-one basis. The RSUs will vest in full on January 21, 2026."}],"balance_after":65710,"source":{"system":"sec-edgar","filing":"0001193125-26-021414","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000119312526021414/ownership.xml","form_type":"4"}},{"id":1097543,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":68857,"kind":"person","name":"Harsh Michael","position":1,"cik":"0001706155","reported_name":"Harsh Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-01T10:25:48.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":5384,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 11, 2026."}],"balance_after":5386,"source":{"system":"sec-edgar","filing":"0000950170-25-091887","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000095017025091887/ownership.xml","form_type":"4"}},{"id":1621676,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":68857,"kind":"person","name":"Harsh Michael","position":1,"cik":"0001706155","reported_name":"Harsh Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2024-02-23T22:00:41.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a stock option award granted on January 2, 2024 pursuant to the Issuer's Non-Employee Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award becomes exercisable in three equal annual installments beginning January 2, 2025."}],"balance_after":600,"derivative":{"exercise_price":1.59,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":600},"source":{"system":"sec-edgar","filing":"0001209191-24-003900","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919124003900/doc4.xml","form_type":"4"}},{"id":1817184,"issuer":{"id":110906,"kind":"organization","name":"Compute Health Acquisition Corp.","symbol":"CPUH"},"owners":[{"id":68857,"kind":"person","name":"Harsh Michael","position":1,"cik":"0001706155","reported_name":"Harsh Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2023-08-03T16:39:05.000Z","date":"2023-08-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects transactions in connection with that certain Business Combination Agreement (the \"Business Combination Agreement\"), dated as of February 9, 2023 and amended as of May 2, 2023, by and among the issuer, Allurion Technologies Opco, Inc. (f/k/a Allurion Technologies, Inc.) (\"Allurion\"), Allurion Technologies, Inc. (f/k/a Allurion Technologies Holdings, Inc.) (\"Pubco\") and the other parties thereto (the \"Business Combination\")."},{"field":"kind","element":"transactionCoding","label":"F5","text":"Pursuant to the terms of that certain First Amendment to the Warrant Agreement, dated as of August 1, 2023, by and between the issuer and Continental Stock Transfer & Trust Company (\"CST\") and that certain Warrant Assignment, Assumption and Amendment Agreement, dated as of August 1, 2023, by and between the issuer and CST, each then-outstanding issuer public warrant acquired from the issuer was assumed by Pubco and converted into 0.6125 warrants to purchase 1.420455 shares of Pubco at an exercise price of $8.10 per whole share."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of that certain First Amendment to the Warrant Agreement, dated as of August 1, 2023, by and between the issuer and Continental Stock Transfer & Trust Company (\"CST\") and that certain Warrant Assignment, Assumption and Amendment Agreement, dated as of August 1, 2023, by and between the issuer and CST, each then-outstanding issuer public warrant acquired from the issuer was assumed by Pubco and converted into 0.6125 warrants to purchase 1.420455 shares of Pubco at an exercise price of $8.10 per whole share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These warrants become exercisable 30 days after the completion of the Business Combination and expire seven years after the completion of the Business Combination or earlier upon redemption or liquidation."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"These warrants become exercisable 30 days after the completion of the Business Combination and expire seven years after the completion of the Business Combination or earlier upon redemption or liquidation."}],"balance_after":0,"derivative":{"exercise_price":11.5,"underlying":"Class A Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001209191-23-044454","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1828608/000120919123044454/doc4.xml","form_type":"4"}},{"id":1817183,"issuer":{"id":110906,"kind":"organization","name":"Compute Health Acquisition Corp.","symbol":"CPUH"},"owners":[{"id":68857,"kind":"person","name":"Harsh Michael","position":1,"cik":"0001706155","reported_name":"Harsh Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class B Common Stock","published_at":"2023-08-03T16:39:05.000Z","date":"2023-08-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"As described in the issuer's registration statement on Form S-1 (File No. 333-252245) under the heading \"Description of Securities--Founder Shares,\" the shares of Class B Common Stock were to automatically convert into shares of Class A Common Stock at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects transactions in connection with that certain Business Combination Agreement (the \"Business Combination Agreement\"), dated as of February 9, 2023 and amended as of May 2, 2023, by and among the issuer, Allurion Technologies Opco, Inc. (f/k/a Allurion Technologies, Inc.) (\"Allurion\"), Allurion Technologies, Inc. (f/k/a Allurion Technologies Holdings, Inc.) (\"Pubco\") and the other parties thereto (the \"Business Combination\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Reflects the conversion of 30,000 shares of the issuer's Class B common stock, par value $0.0001 (\"Class B Common Stock\"), held by Mr. Harsh into 21,120 shares of the issuer's Class A common stock, $0.0001 par value (\"Class A Common Stock\"), pursuant to the terms of that certain Sponsor Support Agreement, dated as of February 9, 2023, by and among the issuer, Compute Health Sponsor LLC, Allurion, Pubco and the other parties thereto, which was entered into in connection with the Business Combination."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects the conversion of 30,000 shares of the issuer's Class B common stock, par value $0.0001 (\"Class B Common Stock\"), held by Mr. Harsh into 21,120 shares of the issuer's Class A common stock, $0.0001 par value (\"Class A Common Stock\"), pursuant to the terms of that certain Sponsor Support Agreement, dated as of February 9, 2023, by and among the issuer, Compute Health Sponsor LLC, Allurion, Pubco and the other parties thereto, which was entered into in connection with the Business Combination."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"As described in the issuer's registration statement on Form S-1 (File No. 333-252245) under the heading \"Description of Securities--Founder Shares,\" the shares of Class B Common Stock were to automatically convert into shares of Class A Common Stock at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"As described in the issuer's registration statement on Form S-1 (File No. 333-252245) under the heading \"Description of Securities--Founder Shares,\" the shares of Class B Common Stock were to automatically convert into shares of Class A Common Stock at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Class A Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-23-044454","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1828608/000120919123044454/doc4.xml","form_type":"4"}},{"id":1817182,"issuer":{"id":110906,"kind":"organization","name":"Compute Health Acquisition Corp.","symbol":"CPUH"},"owners":[{"id":68857,"kind":"person","name":"Harsh Michael","position":1,"cik":"0001706155","reported_name":"Harsh Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-08-03T16:39:05.000Z","date":"2023-08-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":31120,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects transactions in connection with that certain Business Combination Agreement (the \"Business Combination Agreement\"), dated as of February 9, 2023 and amended as of May 2, 2023, by and among the issuer, Allurion Technologies Opco, Inc. (f/k/a Allurion Technologies, Inc.) (\"Allurion\"), Allurion Technologies, Inc. (f/k/a Allurion Technologies Holdings, Inc.) (\"Pubco\") and the other parties thereto (the \"Business Combination\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Reflects the conversion of 30,000 shares of the issuer's Class B common stock, par value $0.0001 (\"Class B Common Stock\"), held by Mr. Harsh into 21,120 shares of the issuer's Class A common stock, $0.0001 par value (\"Class A Common Stock\"), pursuant to the terms of that certain Sponsor Support Agreement, dated as of February 9, 2023, by and among the issuer, Compute Health Sponsor LLC, Allurion, Pubco and the other parties thereto, which was entered into in connection with the Business Combination."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Business Combination Agreement, each share of Class A Common Stock was canceled and converted into the right to receive 1.420455 shares of Pubco common stock, $0.0001 par value."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-044454","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1828608/000120919123044454/doc4.xml","form_type":"4"}},{"id":1817181,"issuer":{"id":110906,"kind":"organization","name":"Compute Health Acquisition Corp.","symbol":"CPUH"},"owners":[{"id":68857,"kind":"person","name":"Harsh Michael","position":1,"cik":"0001706155","reported_name":"Harsh Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-08-03T16:39:05.000Z","date":"2023-08-01","kind":"grant","planned":false,"acquired":true,"shares":21120,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects transactions in connection with that certain Business Combination Agreement (the \"Business Combination Agreement\"), dated as of February 9, 2023 and amended as of May 2, 2023, by and among the issuer, Allurion Technologies Opco, Inc. (f/k/a Allurion Technologies, Inc.) (\"Allurion\"), Allurion Technologies, Inc. (f/k/a Allurion Technologies Holdings, Inc.) (\"Pubco\") and the other parties thereto (the \"Business Combination\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Reflects the conversion of 30,000 shares of the issuer's Class B common stock, par value $0.0001 (\"Class B Common Stock\"), held by Mr. Harsh into 21,120 shares of the issuer's Class A common stock, $0.0001 par value (\"Class A Common Stock\"), pursuant to the terms of that certain Sponsor Support Agreement, dated as of February 9, 2023, by and among the issuer, Compute Health Sponsor LLC, Allurion, Pubco and the other parties thereto, which was entered into in connection with the Business Combination."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects the conversion of 30,000 shares of the issuer's Class B common stock, par value $0.0001 (\"Class B Common Stock\"), held by Mr. Harsh into 21,120 shares of the issuer's Class A common stock, $0.0001 par value (\"Class A Common Stock\"), pursuant to the terms of that certain Sponsor Support Agreement, dated as of February 9, 2023, by and among the issuer, Compute Health Sponsor LLC, Allurion, Pubco and the other parties thereto, which was entered into in connection with the Business Combination."}],"balance_after":31120,"source":{"system":"sec-edgar","filing":"0001209191-23-044454","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1828608/000120919123044454/doc4.xml","form_type":"4"}},{"id":2038205,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":68857,"kind":"person","name":"Harsh Michael","position":1,"cik":"0001706155","reported_name":"Harsh Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2023-02-02T01:30:32.000Z","date":"2023-01-30","kind":"grant","acquired":true,"shares":9634,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option grant becomes exercisable in three equal annual installments beginning January 30, 2024."}],"balance_after":9634,"derivative":{"exercise_price":4.02,"expiration_date":"2033-01-30","underlying":"Common Stock","underlying_shares":9634},"source":{"system":"sec-edgar","filing":"0001209191-23-006050","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919123006050/doc4.xml","form_type":"4"}},{"id":2313827,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":68857,"kind":"person","name":"Harsh Michael","position":1,"cik":"0001706155","reported_name":"Harsh Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2022-03-30T21:15:24.000Z","date":"2022-03-28","kind":"grant","acquired":true,"shares":109492,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option grant becomes exercisable in three equal annual installments beginning March 28, 2023."}],"balance_after":109492,"derivative":{"exercise_price":0.38,"expiration_date":"2032-03-28","underlying":"Common Stock","underlying_shares":109492},"source":{"system":"sec-edgar","filing":"0001209191-22-021619","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919122021619/doc4.xml","form_type":"4"}},{"id":2447199,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":68857,"kind":"person","name":"Harsh Michael","position":1,"cik":"0001706155","reported_name":"Harsh Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2022-01-04T22:05:15.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a stock option award granted on January 3, 2022 pursuant to the Issuer's Non-Employee Director Compensation Policy."}],"balance_after":12000,"derivative":{"exercise_price":0.74,"exercise_date":"2023-01-03","expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-22-000954","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919122000954/doc4.xml","form_type":"4"}},{"id":2753773,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":68857,"kind":"person","name":"Harsh Michael","position":1,"cik":"0001706155","reported_name":"Harsh Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2021-04-07T20:16:52.000Z","date":"2021-04-05","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option grant becomes exercisable in three equal annual installments beginning April 5, 2022."}],"balance_after":25000,"derivative":{"exercise_price":2.64,"expiration_date":"2031-04-05","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-21-025861","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919121025861/doc4.xml","form_type":"4"}},{"id":2771626,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":68857,"kind":"person","name":"Harsh Michael","position":1,"cik":"0001706155","reported_name":"Harsh Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2021-03-25T21:00:55.000Z","date":"2021-01-04","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a stock option award granted on January 4, 2021 pursuant to the Issuer's Non-Employee Director Compensation Policy."}],"balance_after":12000,"derivative":{"exercise_price":0.8,"exercise_date":"2022-01-04","expiration_date":"2031-01-04","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-21-023040","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919121023040/doc4.xml","form_type":"4"}},{"id":3100485,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":68857,"kind":"person","name":"Harsh Michael","position":1,"cik":"0001706155","reported_name":"Harsh Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2020-06-24T12:23:36.000Z","date":"2020-06-23","kind":"other","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":6056,"derivative":{"exercise_price":0.87,"exercise_date":"2019-12-11","expiration_date":"2024-12-11","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-20-038682","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919120038682/doc4.xml","form_type":"4"}},{"id":3100484,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":68857,"kind":"person","name":"Harsh Michael","position":1,"cik":"0001706155","reported_name":"Harsh Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-24T12:23:36.000Z","date":"2020-06-23","kind":"other","acquired":true,"shares":5000,"price":0.87,"value":4350.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes unvested restricted stock units."}],"balance_after":69243,"source":{"system":"sec-edgar","filing":"0001209191-20-038682","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919120038682/doc4.xml","form_type":"4"}},{"id":3114254,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":68857,"kind":"person","name":"Harsh Michael","position":1,"cik":"0001706155","reported_name":"Harsh Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2020-06-10T11:39:26.000Z","date":"2020-06-08","kind":"exercise","acquired":false,"shares":9.618,"price":1143.68,"value":10999.91424,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series A Convertible Preferred Stock has a face value of $1,000 per share and accrues dividends thereon at an annual rate of 6.0%. The face value plus accrued and unpaid dividends of the Series A Convertible Preferred Stock is convertible into common stock at a price per share of $0.87."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series A Convertible Preferred Stock has no expiration date."}],"balance_after":0,"derivative":{"exercise_price":0.87,"exercise_date":"2019-12-11","underlying":"Common Stock","underlying_shares":11386},"source":{"system":"sec-edgar","filing":"0001209191-20-035439","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919120035439/doc4.xml","form_type":"4"}},{"id":3114253,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":68857,"kind":"person","name":"Harsh Michael","position":1,"cik":"0001706155","reported_name":"Harsh Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-10T11:39:26.000Z","date":"2020-06-08","kind":"exercise","acquired":true,"shares":11386,"price":0.87,"value":9905.82,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes unvested restricted stock units."}],"balance_after":64243,"source":{"system":"sec-edgar","filing":"0001209191-20-035439","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919120035439/doc4.xml","form_type":"4"}},{"id":3177604,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":68857,"kind":"person","name":"Harsh Michael","position":1,"cik":"0001706155","reported_name":"Harsh Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T20:45:17.000Z","date":"2020-04-09","kind":"grant","acquired":true,"shares":42857,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted in lieu of the Reporting Person's cash retainer payable under the Issuer's Non-Employee Director\nCompensation Policy for the second, third and fourth quarters of 2020. The restricted stock units vest in three equal installments on the last day\nof each such calendar quarter. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes unvested restricted stock units."}],"balance_after":52857,"source":{"system":"sec-edgar","filing":"0001209191-20-024216","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919120024216/doc4.xml","form_type":"4"}},{"id":3317373,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":68857,"kind":"person","name":"Harsh Michael","position":1,"cik":"0001706155","reported_name":"Harsh Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2020-01-06T21:22:38.000Z","date":"2020-01-02","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a stock option award granted on January 2, 2020 pursuant to the Issuer's Non-Employee Director Compensation Policy."}],"balance_after":12000,"derivative":{"exercise_price":1.9,"exercise_date":"2021-01-02","expiration_date":"2030-01-02","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-20-001796","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919120001796/doc4.xml","form_type":"4"}},{"id":3344786,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":68857,"kind":"person","name":"Harsh Michael","position":1,"cik":"0001706155","reported_name":"Harsh Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2019-12-11T22:49:45.000Z","date":"2019-12-11","kind":"grant","acquired":true,"shares":11056,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The Warrants were issued for no additional consideration in connection with the purchase of the Series A preferred stock."}],"balance_after":11056,"derivative":{"exercise_price":0.87,"exercise_date":"2019-12-11","expiration_date":"2024-12-11","underlying":"Common Stock","underlying_shares":11056},"source":{"system":"sec-edgar","filing":"0001209191-19-060087","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919119060087/doc4.xml","form_type":"4"}},{"id":3344785,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":68857,"kind":"person","name":"Harsh Michael","position":1,"cik":"0001706155","reported_name":"Harsh Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2019-12-11T22:49:45.000Z","date":"2019-12-11","kind":"grant","acquired":true,"shares":9.618,"price":1143.68,"value":10999.91424,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series A preferred stock has a face value of $1,000 per share and accrues dividends thereon at an annual rate of 6.0%.  The face value plus accrued and unpaid dividends of the Series A preferred stock is convertible into common stock at a price per share of $0.87."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series A preferred stock has no expiration date."}],"balance_after":9.618,"derivative":{"exercise_price":0.87,"exercise_date":"2019-12-11","underlying":"Common Stock","underlying_shares":11056},"source":{"system":"sec-edgar","filing":"0001209191-19-060087","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919119060087/doc4.xml","form_type":"4"}},{"id":3344784,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":68857,"kind":"person","name":"Harsh Michael","position":1,"cik":"0001706155","reported_name":"Harsh Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2019-12-11T22:49:45.000Z","date":"2019-12-11","kind":"grant","acquired":true,"shares":89922,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest and become exercisable in three equal annual installments beginning on the one year anniversary of the grant date."}],"balance_after":89922,"derivative":{"exercise_price":0.9,"expiration_date":"2029-12-11","underlying":"Common Stock","underlying_shares":89922},"source":{"system":"sec-edgar","filing":"0001209191-19-060087","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919119060087/doc4.xml","form_type":"4"}},{"id":3488985,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":68857,"kind":"person","name":"Harsh Michael","position":1,"cik":"0001706155","reported_name":"Harsh Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-14T21:39:02.000Z","date":"2019-06-10","kind":"purchase","acquired":true,"shares":500,"price":1.14,"value":570.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.11 to $1.16, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc. (the \"Issuer\"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001209191-19-037236","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919119037236/doc4.xml","form_type":"4"}},{"id":3495259,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":68857,"kind":"person","name":"Harsh Michael","position":1,"cik":"0001706155","reported_name":"Harsh Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-10T20:26:24.000Z","date":"2019-06-07","kind":"purchase","acquired":true,"shares":2800,"price":1.12,"value":3136.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.10 to $1.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4."}],"balance_after":9500,"source":{"system":"sec-edgar","filing":"0001209191-19-035800","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919119035800/doc4.xml","form_type":"4"}},{"id":3495258,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":68857,"kind":"person","name":"Harsh Michael","position":1,"cik":"0001706155","reported_name":"Harsh Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-10T20:26:24.000Z","date":"2019-06-06","kind":"purchase","acquired":true,"shares":6600,"price":1.11,"value":7326.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.09 to $1.16, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc. (the \"Issuer\"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4."}],"balance_after":6700,"source":{"system":"sec-edgar","filing":"0001209191-19-035800","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919119035800/doc4.xml","form_type":"4"}},{"id":3495257,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":68857,"kind":"person","name":"Harsh Michael","position":1,"cik":"0001706155","reported_name":"Harsh Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-10T20:26:24.000Z","date":"2019-06-05","kind":"purchase","acquired":true,"shares":100,"price":1.2,"value":120.0,"ownership":{"direct":true},"balance_after":100,"source":{"system":"sec-edgar","filing":"0001209191-19-035800","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919119035800/doc4.xml","form_type":"4"}},{"id":3576131,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":68857,"kind":"person","name":"Harsh Michael","position":1,"cik":"0001706155","reported_name":"Harsh Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2019-03-28T00:03:39.000Z","date":"2019-03-25","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a stock option award granted on March 25, 2019 pursuant to the Issuer's Non-Employee Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option grant becomes exercisable in three equal annual installments beginning March 25, 2020."}],"balance_after":50000,"derivative":{"exercise_price":3.09,"expiration_date":"2019-03-25","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-19-021511","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919119021511/doc4.xml","form_type":"4"}},{"id":4106494,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":68857,"kind":"person","name":"Harsh Michael","position":1,"cik":"0001706155","reported_name":"Harsh Michael","relationship":{"director":true}}],"security":"Stock Options","published_at":"2018-01-04T22:27:08.000Z","date":"2018-01-02","kind":"grant","acquired":true,"shares":6061,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a stock option award granted on January 2, 2018 pursuant to the Issuer's Non-Employee\nDirector Compensation Policy."}],"balance_after":6061,"derivative":{"exercise_price":4.95,"exercise_date":"2019-01-02","expiration_date":"2026-01-02","underlying":"Common Stock","underlying_shares":6061},"source":{"system":"sec-edgar","filing":"0001654954-18-000113","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000165495418000113/section16.xml","form_type":"4"}},{"id":4307656,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":68857,"kind":"person","name":"Harsh Michael","position":1,"cik":"0001706155","reported_name":"Harsh Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2017-05-23T22:07:55.000Z","date":"2017-05-12","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This amendment is being filed to correct the exercisable date of these Stock Options, which was inadvertantly reported as May 12, 2017. The correct exercisable date is December 31, 2017."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This amendment is being filed to correct the expiration date of these Stock Options, which was inadvertantly reported as May 12, 2022. The\ncorrect expiration date is May 12, 2025."}],"balance_after":6000,"derivative":{"exercise_price":5,"exercise_date":"2017-12-31","expiration_date":"2025-05-12","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001209191-17-034739","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919117034739/doc4a.xml","form_type":"4/A","original_submission_date":"2017-05-16"}},{"id":4307655,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":68857,"kind":"person","name":"Harsh Michael","position":1,"cik":"0001706155","reported_name":"Harsh Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2017-05-23T22:07:55.000Z","date":"2017-05-12","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This amendment is being filed to correct the expiration date of these Stock Options, which was inadvertantly reported as May 12, 2022. The\ncorrect expiration date is May 12, 2025."}],"balance_after":6000,"derivative":{"exercise_price":5,"exercise_date":"2017-05-12","expiration_date":"2025-05-12","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001209191-17-034739","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919117034739/doc4a.xml","form_type":"4/A","original_submission_date":"2017-05-16"}},{"id":4317698,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":68857,"kind":"person","name":"Harsh Michael","position":1,"cik":"0001706155","reported_name":"Harsh Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2017-05-17T01:17:08.000Z","date":"2017-05-12","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":12000,"derivative":{"exercise_price":5,"exercise_date":"2017-05-12","expiration_date":"2022-05-12","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-17-032900","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919117032900/doc4.xml","form_type":"4"}}]}